A formulary of dermatological preparations and background information on therapeutic choices, production and dispensing. 2nd edition
Guidelines for national programmes and other stakeholders, for annexes see http://www.who.int/tb/publications/2012/tb_hiv_policy_9789241503006/en/
Это временное руководство было разработано на основе рекомендаций Стратегической консультативной группы экспер-тов (СКГЭ) по иммунизации на ее внеочередном засе...ании 15 марта 2021 г. (
more
Schistosomiasis is a parasitic disease caused by infection with
Schistosoma trematodes. The disease affects poor rural communities
but has spread to urban areas and to tourists visiting endemic areas
BMC Family Practice201415:165, DOI: 10.1186/1471-2296-15-165
Open Access
Time has seen management for Cystic Fibrosis (CF) advance drastically, most recently in the development of the disease-modifying triple combination therapy ivacaftor/tezacaftor/elexacaftor. There is currently limited evidence regarding both the global epidemiology of CF and access to this transforma...tive therapy - and therefore where needs are not being met. Therefore, this study aims to define gaps in access to CF treatment. The results show that a significant CF patient burden exists in countries where disease-modifying drugs are unavailable, and final figures are likely underestimates. This analysis shows the potential to improve rates of diagnosis and treatment for CF, so a higher percentage of patients receive the most effective triple combination treatment.
more
Interim Assessement Report
The EMA review was started by the Agency’s Committee for Medicinal Products for Human Use (CHMP) to support decision-making by health authorities. This first interim report includes information on seven experimental medicines intended for the treatment of people infecte...d with the Ebola virus:
BCX4430 (Biocryst);
Brincidofovir (Chimerix);
Favipiravir (Fujifilm Corporation/Toyama);
TKM-100802 (Tekmira);
AVI-7537 (Sarepta);
ZMapp (Leafbio Inc.);
Anti-Ebola F(ab’)2 (Fab’entech).
The amount of information available for the seven treatments is highly variable. For some compounds there is no data from use in human subjects available. A small number of treatments have been administered to patients in the current Ebola outbreak as compassionate use. Finally, there are also medicines included in this review that have already been studied in humans, albeit for the treatment of other viral diseases.
more
The document summarizes the infrastructure and activities for Ebola virus disease (EVD) preparedness that are already in place in the Gambia and identifies opportunities for improvement to strengthen the nation’s readiness in the event of an EVD incident.
SIGN 143. A national clinical guideline
Published May 2015, Revised 2018
Documentation des meilleures pratiques et des goulots d’étranglement à la mise en œuvre du programme au Sénégal .
Malawi Integrated Guidelines and Standard Operating Procedures for Providing HIV Services. 3rd edition 2016